Validation of the IHC4 Breast Cancer Prognostic Algorithm Using Multiple Approaches on the Multinational TEAM Clinical Trial

• Published in: Archives of pathology & laboratory medicine (1976) Vol. 140; no. 1; pp. 66 - 74
• Main Authors: Bartlett, John M S, Christiansen, Jason, Gustavson, Mark, Rimm, David L, Piper, Tammy, van de Velde, Cornelis J H, Hasenburg, Annette, Kieback, Dirk G, Putter, Hein, Markopoulos, Christos J, Dirix, Luc Y, Seynaeve, Caroline, Rea, Daniel W
• Format: Journal Article
• Language: English
• Published: United States College of American Pathologists 01.01.2016
• Subjects: Algorithms; Androstadienes - therapeutic use; Antineoplastic Agents - therapeutic use; Biomarkers, Tumor - analysis; Breast cancer; Breast Neoplasms - drug therapy; Breast Neoplasms - mortality; Chemotherapy, Adjuvant; Clinical trials; Disease-Free Survival; Exemestane; Female; Fluorescent Antibody Technique; Health aspects; Humans; Image Interpretation, Computer-Assisted; Immunohistochemistry; Kaplan-Meier Estimate; Medical research; Prognosis; Recurrence (Disease); Tamoxifen; Tamoxifen - therapeutic use; Treatment Outcome

Hormone receptors HER2/neu and Ki-67 are markers of residual risk in early breast cancer. An algorithm (IHC4) combining these markers may provide additional information on residual risk of recurrence in patients treated with hormone therapy. To independently validate the IHC4 algorithm in the multin...